Nicholas Naclerio
CIK: 0001534166
Nicholas Naclerio's purchase track record
Nicholas Naclerio has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/20/2026 | ALMR | $4.00M | +8.7% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALMR | ▼ Sell | Other | 922,152 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 5,510,516 | — | 4/20/2026 | View on chart |
| ALMR | ▲ Buy | Open Market | 235,294 | $4.0M | 4/20/2026 | View on chart |
| ALMR | ▲ Buy | Grant | 5,686 | $0 | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 5,510,516 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 346,020 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 271,782 | — | 4/20/2026 | View on chart |
| ALMR | ▼ Sell | Other | 4,588,364 | — | 4/20/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Alamar Biosciences Sets Q3 2026 Earnings Release Date
Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.
Alamar Biosciences Sets Q3 2026 Earnings Release Date. Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.